Bailard’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $102M | Sell |
731,497
-2,560
| -0.3% | -$358K | 2.34% | 8 |
|
|
2025
Q4 | $90.1M | Buy |
734,057
+65,056
| +10% | +$7.91M | 1.99% | 9 |
|
|
2025
Q3 | $74.3M | Buy |
669,001
+2,956
| +0.4% | +$336K | 1.61% | 11 |
|
|
2025
Q2 | $73.8M | Sell |
666,045
-63
| -0% | -$6.71K | 1.72% | 11 |
|
|
2025
Q1 | $74.6M | Sell |
666,108
-6,801
| -1% | -$702K | 1.93% | 8 |
|
|
2024
Q4 | $62.2M | Buy |
672,909
+157
| +0% | +$14.1K | 1.59% | 12 |
|
|
2024
Q3 | $56.4M | Buy |
672,752
+75
| +0% | +$5.72K | 1.47% | 13 |
|
|
2024
Q2 | $46.2M | Buy |
672,677
+36
| +0% | +$2.4K | 1.27% | 14 |
|
|
2024
Q1 | $49.3M | Sell |
672,641
-866
| -0.1% | -$66.6K | 1.36% | 13 |
|
|
2023
Q4 | $54.6M | Sell |
673,507
-48,838
| -7% | -$3.8M | 1.62% | 12 |
|
|
2023
Q3 | $54.1M | Buy |
722,345
+714,494
| +9,101% | +$55M | 1.79% | 8 |
|
|
2023
Q2 | $605K | Sell |
7,851
-829
| -10% | -$66.1K | 0.02% | 352 |
|
|
2023
Q1 | $720K | Sell |
8,680
-131
| -1% | -$10.8K | 0.03% | 317 |
|
|
2022
Q4 | $756K | Sell |
8,811
-1,897
| -18% | -$150K | 0.03% | 305 |
|
|
2022
Q3 | $661K | Buy |
10,708
+1,292
| +14% | +$81.5K | 0.03% | 294 |
|
|
2022
Q2 | $582K | Buy |
9,416
+252
| +3% | +$15.6K | 0.02% | 344 |
|
|
2022
Q1 | $545K | Sell |
9,164
-692
| -7% | -$44.2K | 0.02% | 384 |
|
|
2021
Q4 | $716K | Sell |
9,856
-588
| -6% | -$40.5K | 0.02% | 335 |
|
|
2021
Q3 | $730K | Buy |
10,444
+1,969
| +23% | +$138K | 0.02% | 323 |
|
|
2021
Q2 | $584K | Sell |
8,475
-5,329
| -39% | -$356K | 0.02% | 382 |
|
|
2021
Q1 | $892K | Sell |
13,804
-626
| -4% | -$40.4K | 0.03% | 274 |
|
|
2020
Q4 | $841K | Buy |
14,430
+2,080
| +17% | +$126K | 0.04% | 238 |
|
|
2020
Q3 | $780K | Buy |
12,350
+1,657
| +15% | +$115K | 0.04% | 227 |
|
|
2020
Q2 | $823K | Sell |
10,693
-59,434
| -85% | -$4.55M | 0.05% | 215 |
|
|
2020
Q1 | $5.24M | Buy |
70,127
+9,364
| +15% | +$647K | 0.37% | 67 |
|
|
2019
Q4 | $3.95M | Sell |
60,763
-59,307
| -49% | -$3.86M | 0.22% | 102 |
|
|
2019
Q3 | $7.61M | Buy |
120,070
+70,558
| +143% | +$4.61M | 0.46% | 50 |
|
|
2019
Q2 | $3.35M | Sell |
49,512
-53
| -0.1% | -$3.49K | 0.2% | 108 |
|
|
2019
Q1 | $3.22M | Buy |
49,565
+5,929
| +14% | +$394K | 0.2% | 107 |
|
|
2018
Q4 | $2.73M | Sell |
43,636
-2,531
| -5% | -$177K | 0.18% | 109 |
|
|
2018
Q3 | $3.56M | Sell |
46,167
-1,352
| -3% | -$102K | 0.21% | 103 |
|
|
2018
Q2 | $3.37M | Buy |
47,519
+919
| +2% | +$64.9K | 0.2% | 110 |
|
|
2018
Q1 | $3.51M | Buy |
46,600
+8,518
| +22% | +$677K | 0.22% | 107 |
|
|
2017
Q4 | $2.73M | Sell |
38,082
-6,694
| -15% | -$508K | 0.17% | 140 |
|
|
2017
Q3 | $3.63M | Sell |
44,776
-3,737
| -8% | -$286K | 0.28% | 91 |
|
|
2017
Q2 | $3.43M | Buy |
48,513
+806
| +2% | +$53.6K | 0.28% | 91 |
|
|
2017
Q1 | $3.24M | Buy |
47,707
+787
| +2% | +$55.3K | 0.27% | 93 |
|
|
2016
Q4 | $3.36M | Sell |
46,920
-2,247
| -5% | -$167K | 0.31% | 84 |
|
|
2016
Q3 | $3.89M | Buy |
49,167
+21,398
| +77% | +$1.74M | 0.36% | 70 |
|
|
2016
Q2 | $2.32M | Buy |
27,769
+24,110
| +659% | +$2.14M | 0.28% | 89 |
|
|
2016
Q1 | $336K | Sell |
3,659
-2,341
| -39% | -$211K | 0.05% | 185 |
|
|
2015
Q4 | $607K | Sell |
6,000
-13,202
| -69% | -$1.37M | 0.27% | 119 |
|
|
2015
Q3 | $1.89M | Buy |
+19,202
| New | +$2.13M | 0.29% | 59 |
|
Other funds holding GILD
VCM
VPM
Bailard's GILD Position: Q1 2026 in Review
Bailard reduced its Gilead Sciences (GILD) stake by 0.35% in Q1 2026, selling an estimated $358K and leaving 731,497 shares worth $102M. The position accounts for 2.34% of the portfolio, ranked #8.
Bailard first reported a position in GILD in Q3 2015 and has held it in 43 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Bailard held 731,497 shares of Gilead Sciences worth $102M as of Q1 2026.
- Bailard sold 2,560 Gilead Sciences shares in Q1 2026, an estimated $358K.
- Gilead Sciences made up 2.34% of Bailard's portfolio in Q1 2026, its #8 holding.
- Bailard first reported a position in Gilead Sciences in Q3 2015 and has held it in 43 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.